Core Viewpoint - The announcement highlights a patent review initiated by Conjupro Biotherapeutics, a subsidiary of CSPC Pharmaceutical Group, questioning the validity of a patent held by Gilead Sciences (China) Co., Ltd. [1][2] Group 1: Patent Review and Legal Context - CSPC's Conjupro Biotherapeutics has filed a review with the USPTO challenging the validity of Gilead's U.S. patent (Patent No. 12,234,236) claims 1-9, 12-17, and 21-25 [1] - The compound structure of CSPC's pending application (Compound 10) is identical to Gilead's patented Compound 1, which was granted by the USPTO on February 25, 2025 [2] - Gilead's management received a global licensing request from CSPC regarding the GLP-1R agonist Compound 1 in late March 2025, which Gilead declined [2] Group 2: Company Confidence and Current Operations - The company expresses confidence in the validity of its patent and is prepared to take necessary legal actions to defend its intellectual property if the review proceeds [3] - Currently, the review does not pose any potential impact on the group's operations, and the company will closely monitor the situation [3]